MX2019012431A - Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. - Google Patents
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.Info
- Publication number
- MX2019012431A MX2019012431A MX2019012431A MX2019012431A MX2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A MX 2019012431 A MX2019012431 A MX 2019012431A
- Authority
- MX
- Mexico
- Prior art keywords
- ahr inhibitors
- indole
- inhibitors
- indole ahr
- ahr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención proporciona compuestos útiles como inhibidores de AHR, composiciones de los mismos y métodos para usar los mismos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762488476P | 2017-04-21 | 2017-04-21 | |
US201762592542P | 2017-11-30 | 2017-11-30 | |
US201862658454P | 2018-04-16 | 2018-04-16 | |
PCT/US2018/028532 WO2018195397A2 (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012431A true MX2019012431A (es) | 2020-08-03 |
Family
ID=63856153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012431A MX2019012431A (es) | 2017-04-21 | 2018-04-20 | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
Country Status (15)
Country | Link |
---|---|
US (4) | US10570138B2 (es) |
EP (1) | EP3612030A4 (es) |
JP (2) | JP7232244B2 (es) |
KR (1) | KR20190141722A (es) |
CN (1) | CN110831600B (es) |
AU (1) | AU2018256459B2 (es) |
BR (1) | BR112019021992A2 (es) |
CA (1) | CA3059939A1 (es) |
CL (1) | CL2019003015A1 (es) |
CO (1) | CO2019011584A2 (es) |
IL (1) | IL270025B2 (es) |
MX (1) | MX2019012431A (es) |
SG (1) | SG11201909710XA (es) |
TW (1) | TWI778050B (es) |
WO (1) | WO2018195397A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3555097T2 (ro) | 2016-12-16 | 2022-12-31 | Janssen Pharmaceutica Nv | Compuși imidazo[4,5-d]pirolo[2,3-b]piridină ca inhibitori ai kinazelor Janus |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
TWI778050B (zh) | 2017-04-21 | 2022-09-21 | 美商醫肯納腫瘤學公司 | 吲哚ahr抑制劑及其用途 |
FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
MX2020001793A (es) | 2017-08-17 | 2020-07-22 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |
WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
CA3090150A1 (en) | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | Ahr modulators |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
EA202190654A1 (ru) | 2018-09-07 | 2021-05-27 | Оцука Фармасьютикал Ко., Лтд. | Гетероциклическое соединение |
WO2020081636A1 (en) * | 2018-10-16 | 2020-04-23 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
WO2020081840A1 (en) * | 2018-10-17 | 2020-04-23 | Magenta Therapeutics Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
KR20210110797A (ko) * | 2018-11-30 | 2021-09-09 | 셀룰래리티 인코포레이티드 | 조혈 줄기세포 및 전구세포의 활성화에 사용하기 위한 방향족 화합물 |
CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
AU2020228385A1 (en) * | 2019-02-27 | 2021-07-29 | Takeda Pharmaceutical Company Limited | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
WO2021022061A1 (en) * | 2019-07-30 | 2021-02-04 | Oregon State University | Aryl hydrocarbon receptor activators |
AU2020386967A1 (en) * | 2019-11-22 | 2022-07-07 | Senda Biosciences, Inc. | Pyridopyrimidinone derivatives as AHR antagonists |
CN115279764A (zh) | 2019-11-26 | 2022-11-01 | 医肯纳肿瘤学公司 | 多晶型咔唑衍生物及其用途 |
CN114728987A (zh) * | 2019-11-26 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的1,8-萘啶-2-酮化合物 |
US20230026232A1 (en) | 2019-11-26 | 2023-01-26 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
CN115244048A (zh) | 2020-02-26 | 2022-10-25 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的吡啶并嘧啶衍生物 |
AU2021242143A1 (en) * | 2020-03-27 | 2022-10-20 | Dong-A St Co., Ltd. | Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators |
US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
WO2022029063A1 (en) * | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
WO2022094567A1 (en) | 2020-10-28 | 2022-05-05 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
CN114644627A (zh) * | 2020-12-18 | 2022-06-21 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
CN112656789A (zh) * | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Ficz在抑制肿瘤细胞迁移中的应用 |
CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
WO2023020512A1 (zh) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 |
WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
WO2023033740A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
CN115093400B (zh) * | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂及其用途和制备方法 |
WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
CN115925684A (zh) * | 2021-12-03 | 2023-04-07 | 徐诺药业(南京)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
WO2023135057A1 (en) | 2022-01-11 | 2023-07-20 | Deutsches Krebsforschungszentrum | Bicyclic triazine derivatives for the treatment of cancer |
WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
CN115804776A (zh) * | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用 |
CN116482278B (zh) * | 2023-05-06 | 2024-02-09 | 广州清瑞生物科技有限责任公司 | 一种用于检测阿昔洛韦的对照品的制备方法 |
CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
EP1343506A1 (de) | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
EP1426046A4 (en) * | 2001-09-14 | 2005-11-02 | Shionogi & Co | NEW USE OF TRICYCLIC COMPOUNDS |
JP2006501260A (ja) * | 2002-09-04 | 2006-01-12 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
AR041291A1 (es) * | 2002-09-19 | 2005-05-11 | Schering Corp | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
AU2005323311A1 (en) * | 2004-11-23 | 2006-07-13 | Venkateswara Rao Batchu | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them |
PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
EA026785B1 (ru) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Модуляторы индоламин 2,3-диоксигеназы и способы их применения |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
MY146474A (en) * | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2707308C (en) | 2007-11-30 | 2016-08-02 | Newlink Genetics Corporation | Ido inhibitors |
JP5643105B2 (ja) * | 2007-12-14 | 2014-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規イミダゾ[1,2−a]ピリジン及びイミダゾ[1,2−b]ピリダジン誘導体 |
JP2011523616A (ja) | 2008-05-29 | 2011-08-18 | サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン | チタン酸アルミニウムを含有する多孔質構造体 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
RU2646139C1 (ru) | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Анти-gitr-антитела |
ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
CN102791738B (zh) | 2009-12-10 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
PL2542256T3 (pl) | 2010-03-04 | 2020-01-31 | Macrogenics, Inc. | Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania |
EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
EP2621926B1 (en) * | 2010-09-30 | 2017-08-30 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
NZ612512A (en) | 2010-12-09 | 2015-03-27 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
WO2012143144A1 (en) | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
WO2013086436A1 (en) * | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
JP6242804B2 (ja) | 2011-12-15 | 2017-12-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトcsf−1rに対する抗体及びその使用 |
MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
KR20220162819A (ko) | 2012-05-11 | 2022-12-08 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
US9637491B2 (en) | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
MX2019011138A (es) | 2017-04-12 | 2020-01-27 | Magenta Therapeutics Inc | Antagonistas del receptor de hidrocarburo de arilo y sus usos. |
TWI778050B (zh) | 2017-04-21 | 2022-09-21 | 美商醫肯納腫瘤學公司 | 吲哚ahr抑制劑及其用途 |
-
2018
- 2018-04-20 TW TW107113564A patent/TWI778050B/zh active
- 2018-04-20 SG SG11201909710X patent/SG11201909710XA/en unknown
- 2018-04-20 CA CA3059939A patent/CA3059939A1/en active Pending
- 2018-04-20 AU AU2018256459A patent/AU2018256459B2/en active Active
- 2018-04-20 EP EP18787414.4A patent/EP3612030A4/en active Pending
- 2018-04-20 US US15/958,586 patent/US10570138B2/en active Active
- 2018-04-20 MX MX2019012431A patent/MX2019012431A/es unknown
- 2018-04-20 KR KR1020197034489A patent/KR20190141722A/ko active IP Right Grant
- 2018-04-20 JP JP2020507495A patent/JP7232244B2/ja active Active
- 2018-04-20 CN CN201880038301.XA patent/CN110831600B/zh active Active
- 2018-04-20 BR BR112019021992A patent/BR112019021992A2/pt unknown
- 2018-04-20 WO PCT/US2018/028532 patent/WO2018195397A2/en active Application Filing
-
2019
- 2019-10-17 IL IL270025A patent/IL270025B2/en unknown
- 2019-10-18 CO CONC2019/0011584A patent/CO2019011584A2/es unknown
- 2019-10-21 CL CL2019003015A patent/CL2019003015A1/es unknown
- 2019-10-30 US US16/668,070 patent/US10689388B1/en active Active
-
2020
- 2020-04-08 US US16/843,606 patent/US11358969B2/en active Active
-
2022
- 2022-05-06 US US17/662,246 patent/US20230028336A1/en active Pending
- 2022-06-06 JP JP2022091740A patent/JP2022116319A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
TW201841917A (zh) | 2018-12-01 |
JP2020517734A (ja) | 2020-06-18 |
US11358969B2 (en) | 2022-06-14 |
EP3612030A2 (en) | 2020-02-26 |
IL270025B1 (en) | 2023-01-01 |
CA3059939A1 (en) | 2018-10-25 |
BR112019021992A2 (pt) | 2020-06-09 |
AU2018256459B2 (en) | 2023-12-07 |
CN110831600B (zh) | 2023-10-17 |
WO2018195397A2 (en) | 2018-10-25 |
US10689388B1 (en) | 2020-06-23 |
US20180327411A1 (en) | 2018-11-15 |
SG11201909710XA (en) | 2019-11-28 |
IL270025B2 (en) | 2023-05-01 |
JP2022116319A (ja) | 2022-08-09 |
CL2019003015A1 (es) | 2020-03-27 |
KR20190141722A (ko) | 2019-12-24 |
TWI778050B (zh) | 2022-09-21 |
WO2018195397A3 (en) | 2018-12-13 |
AU2018256459A1 (en) | 2019-11-07 |
US10570138B2 (en) | 2020-02-25 |
US20230028336A1 (en) | 2023-01-26 |
US20200331917A1 (en) | 2020-10-22 |
IL270025A (es) | 2019-12-31 |
JP7232244B2 (ja) | 2023-03-08 |
CN110831600A (zh) | 2020-02-21 |
EP3612030A4 (en) | 2021-04-28 |
CO2019011584A2 (es) | 2020-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012431A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
NZ725917A (en) | Novel polymerase-i inhibitors, uses and methods for making them | |
MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF |